Ardelyx vs Arcutis Biotherapeutics
Ardelyx reported revenue of $407 million in fiscal 2025, about the same as Arcutis Biotherapeutics' $376 million in fiscal 2025. Ardelyx's revenue grew 22.1% in its latest year, and Arcutis Biotherapeutics' grew 91.3%. Ardelyx had an operating margin of -10.1%, against -3.2% at Arcutis Biotherapeutics. Free cash flow was −$44 million at Ardelyx and −$6 million at Arcutis Biotherapeutics.
Side by side
| Ardelyx | Arcutis Biotherapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $407M | $376M |
| Revenue growth | 22.1% | 91.3% |
| Revenue growth a year, last 5 years | 121.7% | — |
| Gross margin | 90.3% | 90.2% |
| Operating margin | −10.1% | −3.2% |
| Net margin | −15.1% | −4.3% |
| Free cash flow | −$44M | −$6M |
| Free cash flow margin | −10.8% | −1.7% |
| Return on capital | −36.1% | −16.9% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 2.5% | 5.2% |
| Last close | $3.09 | $28.26 |
| P/E at the last close | — | 134.6× |
| Insider trades, last 12 months | — | sold $12.2 million |
| Piotroski F-score | 2 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ArdelyxArcutis Biotherapeutics
Operating margin
Percent of revenue
ArdelyxArcutis Biotherapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ArdelyxArcutis Biotherapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ardelyx and Arcutis Biotherapeutics pages.